Edwards Lifesciences Shareholders Approve Expanded Equity Incentive Plan

Edwards Lifesciences ( (EW) ) has issued an announcement.

At its Annual Meeting of Stockholders held on May 7, 2026, Edwards Lifesciences shareholders approved an amendment and restatement of the company’s Long-Term Stock Incentive Compensation Program, increasing the pool of shares available for issuance by 7,000,000 to a total limit of 341,500,000 shares, thereby expanding capacity for equity-based compensation. All director nominees were elected for new terms, shareholders backed the advisory vote on named executive officer pay, and ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for 2026, reinforcing continuity in the company’s governance, leadership, and compensation framework.

These outcomes collectively signal strong investor support for Edwards Lifesciences’ current strategic direction, executive team, and incentive structures, and the expanded stock plan is likely to enhance the company’s ability to attract and retain talent in a competitive medtech labor market. The approvals may also underscore shareholder confidence in the company’s long-term growth prospects and governance stability, which can influence market perception and stakeholder alignment around its ongoing operational and financial objectives.

The most recent analyst rating on (EW) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Edwards Lifesciences stock, see the EW Stock Forecast page.

Spark’s Take on EW Stock

According to Spark, TipRanks’ AI Analyst, EW is a Outperform.

The score is supported most by strong financial fundamentals (high margins and extremely low leverage) and a constructive earnings outlook with reaffirmed 2026 growth/EPS guidance and durable structural-heart momentum. Offsetting this are a relatively rich valuation (P/E ~30) and only moderate technical strength, alongside noted volatility in cash conversion and near-term spending/tax headwinds.

To see Spark’s full report on EW stock, click here.

More about Edwards Lifesciences

Edwards Lifesciences Corporation is a Delaware-based medical technology company focused on cardiovascular innovations, including products such as heart valves and critical care monitoring systems. The company operates globally, serving hospitals and healthcare providers with devices and therapies aimed at improving outcomes for patients with structural heart disease and critical care needs.

Average Trading Volume: 5,134,298

Technical Sentiment Signal: Strong Buy

Current Market Cap: $47.65B

For detailed information about EW stock, go to TipRanks’ Stock Analysis page.